Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinaseXiaoyong Fu, Rachel Schiff, Barry R. Davies et al.|Breast Cancer Research|2014Cited by 70
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistanceGladys Morrison, Rachel Schiff, Xiaoyong Fu et al.|Breast Cancer Research and Treatment|2014Cited by 61